---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-004771"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:39:29.880368+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Genprex announces $4M registered direct offering of common stock and warrants

## Summary
- Sold 3,809,524 shares and warrants to purchase same number at $1.05 combined price.
- Gross proceeds ~$4M; net proceeds for working capital.
- Warrants exercisable at $1.10, expire 5 years from issuance.
- Closing expected March 1, 2023; A.G.P./Alliance Global Partners as placement agent.
- Offering under effective shelf registration statement (S-3).

## SEC filing metadata
- accession: 0001437749-23-004771
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774923004771/0001437749-23-004771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774923004771/gnpx20230226_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-004771
- JSON: https://secwatch.observer/filing/0001437749-23-004771.json
- Plain text: https://secwatch.observer/filing/0001437749-23-004771.txt

## Key facts
- Material Agreements
  Genprex, Inc. entered into Securities Purchase Agreement with accredited healthcare-focused institutional investor valued at aggregate gross proceeds approximately $4.0 million (effective 2023-02-26).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: accredited healthcare-focused institutional investor
  - Value: aggregate gross proceeds approximately $4.0 million
  - Effective: 2023-02-26
  source text: On February 26, 2023, Genprex, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an accredited healthcare-focused institutional investor (the “Purchaser”) pursuant to which the Company agreed to issue and sell to the Purchaser 3,809,524 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”) and common warrants to purchase an aggregate of 3,809,524 shares of Common Stock (the “Warrants”), in a registered direct offering (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774923004771/0001437749-23-004771-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.